The financing dose-response curve: how much is too much?

For biotechs, how much is too much? We’re all too aware of the rate of biotech company failures at the moment. This includes venture-backed companies that have raised well in excess of $100m,...
Learn More

TTOs: Lost in Translation?

It's not business as usual: While the halls of biopharma partnering conferences have refilled, it is definitely not business as usual in the industry. Valuations are down sharply from their pandemic...
Learn More

Is it ever too early to consider new drug pricing strategy?

Is it ever too early to consider new drug pricing strategy?
Learn More

Do Price and Value Assumptions Belong in a Target Product Profile?

We often get pushback from clients about the merit of including launch price assumptions and value proposition statements in the target product profile (TPP) for early-stage development programs....
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Pharmaceutical Patents: an overview

Protecting new treatments and innovations is critical for drug developers. In this article, we provide of an overview of the history of patents, what a patent is, the general process to obtain one...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.